Email Facebook Twitter

Exclusive: Hayden Locke, CEO Emmerson plc, a low cost high margin potash investment | Watch Now

Exclusive: Hayden Locke, CEO Emmerson plc, a low cost high margin potash investment
Richard Slape, Oil consultant - Avoiding Losers and Picking Winners, his personal strategy

Member Info for EyeGuy

Send a private message to EyeGuy

Member Since: Fri, 15th Jul 2011

Number of Share Chat Posts (all time): 3,298
Number of Share Chat Posts (last 30 days): 235

Last Posted: Wed 21:58

Post Distribution over the last 30 days

Wed 21:58

- news due on phase 2 readout next week as per rnd
- in intermedia readout, 8 out the 20 subjects with metastatic breast cancer showed a positive response to SFX-01
- drugs used before SFX-01 will command annual revenues of $10 billion within 2 years.
- SFX-01 also used in phase 2 subarachnoid haemorrhage. Full readout due summer
- company presentation suggests initial payments of between $50 and $250 by Pharma majors if successful plus double digit royalties.
- freefloat circa 36%. Lots of II’s holding

Wed 17:54

Wel I said 20p and it’s well over that.
25p tomorrow imo at least. Very limited stock. Broker target £1.13
Wed 17:12

26% up finish. This site is wrong
Wed 16:18

and from interim update:
SFX-01isprovingtobewelltoleratedwithnosafetyconcernsarising ? SFX-01showsencouragingearlysignsofanti-tumouractivity: - Ofthefirst 20patients,4patientshadtheirprogressive diseasestabilisedfor atleast24weeksand afurther2for18weeks - Twopatientsthat,atonescan,showedapartialresponse(i.e.tumourshrinkageover30%) ? PrincipalInvestigator,DrSachaHowelloftheChristieHospital,UK,said: “The design of the STEM study, adding the drug to endocrine therapy on which a patient’s cancer was progressing, sets a high bar for SFX-01. In light of this, these interim results are highly encouraging. Objective responses indicate activity in this setting, and disease stabilisation for 6-12+ months representsclinicallymeaningfulprolongationofresponse. . .”
Wed 16:17

no stock pal: read this
Incidence of ER+ metastatic breast cancer is approximately 130,0001 in US and Europe ? CDK4/6 inhibitors are now first line treatment, in combination with hormone therapy ? Pfizer (Ibrance®/palbociclib), Novartis (Kisqali®/ribociclib) and Eli Lilly (Versenio®/abemaciclib ) are the key players with sales forecasts of $4.4bn, $0.3bn and $0.17bn respectively in 2018e2 ? CDK4/6 inhibitor sales forecast to reach c.$9bn by 2021e2 ? With hormone therapy after c.25 months on average, patients become resistant to CDK4/6 inhibitors ? Potential of SFX-01 after CDK4/6 inhibitor therapy: a unique mechanism of action and a more favourable side-effect profile
Wed 16:14

28% up now pal. Don't forget SFX-01 has multi uses. Next readouts for Subarachnoid haemorrhage due Late summer. This drugs for metastatic breast cancer used prior to SFX-01 market is worth $10 billion annually
should be a good week
Wed 15:54

25% up nice
Wed 15:51

huge tick up. 22p ask
Wed 15:49

NT to buy - this should fly
Wed 15:47

21p paid
Wed 15:47

kezzman- that isn't true because SFX-01 is also used in subarachnoid haemorrhage with readouts due late summer. Not a one trick pony at all pal.
Wed 14:21

yep big news for me. took a few k here.
Wed 14:20

On 19 March 2019, the Company received a clarificatory letter from EBIOSS in relation to the terms of the Agreement and the Parties' intentions regarding the potential use of EQTEC's technology. EBIOSS has confirmed that, in respect of waste treatment and disposal projects, the Parties will use EQTEC's gasification technology, subject to successful completion of Urbaser technical due diligence and all parties, including EQTEC, agreeing terms, including the commercial basis of any contract. EQTEC confirms that it will conduct due diligence on any potential opportunities that are presented to it by the Parties pursuant to the Agreement.

Ian Price, CEO of EQTEC plc, commented: "We are pleased to note the Agreement between EBIOSS and Urbaser, and we are encouraged by this statement of intent by the Parties to use our technology and the further validation that this would bring to the Group.
Wed 14:19

too some. the agreement has been clarified. that is the point. great news
Wed 14:08

Im in at 1.10 ish.
Wed 13:48

Nice rise well done all. I Think EVG will do the same next week so sticking with them
Wed 11:49

19 ask now. come on 20p ;-)
Wed 08:43

It tells me there is limited stock. Every buy ticks this up. So should build in anticipation of news next week
Wed 08:30

Well I can’t buy any volume at 18.5p and I can sell at over 18p
So what does that tell you son?
Wed 08:22

Moving. Think this will be over 20p today

Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days

Member Login

Forgotten your password?


Don't have an account? Click here to Register Free!

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.